In conclusion, this study for the first time showed Ginsenoside Rh7 can suppress the expression of ILF3-AS1, which could competitively bind with miR-212, thus leading to the down-regulation of SMAD1 and suppression of NSCLC progression (Figure 10). The gene discussed is ILF3; the disease is non-small cell lung carcinoma.